Guidelines for Pharmacovigilance and Medicine Information System in Rwanda

February 2011
Purpose

The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to patients.

This guideline addresses specifically the issues on what to report, why to report, when to report, where to report and how to report.

Enquiries and feedback

The National Pharmacovigilance and Medicine Information Center (NPMIC), in consultation with various stakeholders, will review this guideline and tools periodically, to ensure that they continue to meet the goals of the pharmacovigilance system.

All enquiries and feedback regarding the suitability and practicability of the various tools in the guidelines should be addressed to:

The Pharmacy Task Force,
Ministry Of Health
Desk of Medicine Information
P.O. Box 84
Kigali, Rwanda
Telephone: 114
E-mail: ptfmoh@yahoo.com
Website: www.moh.gov.rw

Citation

This document will be cited as:
# CONTENTS

Acknowledgments .......................................................................................................................... v  
Acronyms and Abbreviations ....................................................................................................... vii  
Foreword ...................................................................................................................................... viii  

Introduction ................................................................................................................................ 1  
  Establishment of the National Pharmacovigilance and Medicines Information Center ........ 2  
  Overarching Goal of the NPMIC .......................................................................................... 2  
  Scope of Pharmacovigilance and Medicine Information System in Rwanda ...................... 2  
  Importance of Pharmacovigilance ...................................................................................... 3  
  Importance of Unbiased Medicine Information .............................................................. 3  

Adverse Event Notification System for Pharmacovigilance System ....................................... 5  
  Notification System ........................................................................................................... 5  
  Roles and Responsibilities in Relation to Pharmacovigilance and Medicine Information ..... 7  
  The NMRA ....................................................................................................................... 10  
  Other Stakeholders ........................................................................................................... 11  

Medicine Information ................................................................................................................. 13  
  Literature Scan for Relevant Safety Alerts ......................................................................... 13  
  Requesting Medicine Information ................................................................................... 13  
  Information, Education, Communication Materials, and NPMIC Publications .............. 13  
  Medicine Promotion and Advertising ............................................................................. 13  

Pharmacovigilance Methods ....................................................................................................... 14  
  Spontaneous Reporting ................................................................................................... 14  
  Active Surveillance .......................................................................................................... 19  
  Some Active Surveillance Methods to be Used in Rwanda ........................................... 20  

Safety Monitoring of Herbal Medicines in the National Pharmacovigilance System .......... 22  

Tools for Medicine Safety Surveillance Activities ........................................................................ 23  
  Adverse Event Notification Form .................................................................................. 23  
  Medicine Information Request Form ............................................................................. 23  
  Causality Assessment Tool ............................................................................................ 24  
  Adverse Event Severity Grading Scale .......................................................................... 24  
  Medication Error Assessment Tool .............................................................................. 24  
  Patient Alert Card ........................................................................................................... 24  
  Glossary of Medicine Safety Terms ............................................................................. 24  

Capacity Building ....................................................................................................................... 26  

Monitoring and Evaluation ......................................................................................................... 27  

Annex A. Adverse Event Notification Form (French) ................................................................ 28  
Annex B. Adverse Event Notification Form (English) ........................................................... 31  
Annex C. Poor Medicine Quality Notification Form (French) ............................................... 33
Annex D. Poor Medicine Quality Notification Form (English) ................................................... 35
Annex E. Medicine Information Request Form........................................................................... 37
Annex F. WHO Causality Assessment Criteria ........................................................................... 38
Annex G. WHO Toxicity Grading Scale ..................................................................................... 39
Annex H. Medication Error Reporting and Prevention Scale....................................................... 43
Annex I. Patient Alert Card (English) ........................................................................................... 44
Annex J. Patient Alert Card (Kinyarwanda) ............................................................................... 45
Annex K. Glossary of Medicine Safety Terms ............................................................................ 46
ACKNOWLEDGMENTS

The Pharmacy Task Force, Ministry of Health, would like to thank all those who contributed in all ways by providing reference materials, technical or financial support and helped to develop this Guideline for Pharmacovigilance and Medicine Information System in Rwanda.

Support from Management Sciences for Health’s Strengthening Pharmaceutical Systems (SPS) Program office in Kigali is much appreciated. The staff, through funds from US Agency for International Development and the President’s Emergency Program for AIDS Relief, facilitated the whole process by offering technical assistance and helped to disseminate the guideline.

The valuable remarks of the reviewers and editors in providing their expert comments and guidance is also much appreciated.

Gratitude is extended to all members of the Pharmacy Task Force, Ministry of Health who offered valuable contributions towards development and production of this document.

Contributors

The Pharmacy Task Force, Ministry of Health, acknowledges the immense contribution of the following for their research, compilation and commitment in developing this document:

Ph’ Alexis Ruzindaza Pharmacy Task Force (Ministry of Health)
Ph. John Patrick Mwesigye Pharmacy Task Force (Ministry of Health)
Ph. Denis Victor Nkundineza Pharmacy Task Force (Ministry of Health)
Ph. Penelope Ingabire Pharmacy Task Force (Ministry of Health)
Ph. Joseph Kabatende Pharmacy Task Force (Ministry of Health)
Ph. Patrick Nganji Pharmacy Task Force (Ministry of Health)
Ph. Joyce Icyimpaye TRAC Plus HIV Unit
Ph. Ladislas Bizimana TRAC Plus HIV Unit
Mrs. Mukashema Jacqueline TRAC Plus Tuberculosis Unit
M. Maurice Gatera Maternal and Child Health, Programme Elargi de Vaccination
Dr. Jackson Sebeza* TRAC Plus Malaria Unit
Mireille Muhimpundu* SPS
Anicet Nyawakira SPS
Ines Buki Gege SPS
Felix Hitayezu SPS
Aline Mukerabirori SPS
Patrick Gaparayi SPS
Jude Nwokike SPS
Mark Morris SPS
Mohan Joshi SPS

a = Pharmacist
b = Has left the organization
*
The Pharmacy Task Force, Ministry of Health acknowledges the feedback, expert comments, and guidance received from the following reviewers and editors.

**Reviewers**

Dr. Charles Karangwa, Rwanda National University  
Dr. Pierre Claver, Kayumba Rwanda National University  
Professor Justin Kadima Ntokamunda, Rwanda National University  
Ph Stella Matutina Tuyisenge, World Health Organization  
Dr. Ruliisa Steven, Rwanda Medical Association  
Professor Andy Stergachis, University of Washington

**Editors**

The Center for Pharmaceutical Management
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>adverse drug reaction</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>DTC</td>
<td>Drug and Therapeutics Committee</td>
</tr>
<tr>
<td>GoR</td>
<td>Government of Rwanda</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency syndrome</td>
</tr>
<tr>
<td>MAH</td>
<td>Marketing authorization holder</td>
</tr>
<tr>
<td>MoH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MSC</td>
<td>Medicine Safety Committee</td>
</tr>
<tr>
<td>MSH</td>
<td>Management Sciences for Health</td>
</tr>
<tr>
<td>NMC</td>
<td>National Medicines Committee</td>
</tr>
<tr>
<td>NMRA</td>
<td>National Medicine Regulatory Authority</td>
</tr>
<tr>
<td>NPMIC</td>
<td>National Pharmacovigilance and Medicine Information Center</td>
</tr>
<tr>
<td>PHP</td>
<td>public health program</td>
</tr>
<tr>
<td>RFMA</td>
<td>Rwanda Food and Medicines Authority</td>
</tr>
<tr>
<td>SOP</td>
<td>standard operating procedure</td>
</tr>
<tr>
<td>SPS</td>
<td>Strengthening Pharmaceutical Systems [Program]</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TRAC</td>
<td>Treatment and Research AIDS Center</td>
</tr>
<tr>
<td>UMC</td>
<td><em>The Uppsala Monitoring Centre</em></td>
</tr>
<tr>
<td>WHO</td>
<td>WHO</td>
</tr>
</tbody>
</table>
FOREWORD

On June 26, 2010, the Rwanda Cabinet approved the Food and Drug Act developed by the Ministry of Health which identifies the Rwanda Food and Medicines Authority (RFMA) as the regulatory board of all medicine- and food-related issues. This document is now in the approval process by the Rwanda Parliament. One of the RFMA’s core mandates is to ensure that the medicines used in the country are of good quality, safe, and efficacious.

As the RFMA is not yet established, the Ministry of Health has established a Pharmacy Task Force which performs most activities related to pharmaceuticals regulations, among them pharmacovigilance and medicine information.

Medicines despite their obvious benefits can also cause adverse drug reactions (ADR) which can be serious or even fatal. Most often these ADRs are preventable. Because of our nascent pharmacovigilance system, it is true that the actual financial burden on our health care system from unreported and undetected ADRs remains unknown but could be huge if the estimates from the countries with developed systems are anything to go by.

The National Pharmacovigilance and Medicine Information Center in the Ministry of Health has been actively involved in designing tools and guidelines for detection and reporting of adverse events.

In 2008, development of the *Guideline for Pharmacovigilance and Medicine Information System in Rwanda* began and the final guidelines were adopted by the General Senior Management Meeting of Ministry of Health in February 2011. This development was followed by sensitization of 27 central health care workers who took part in a training of trainers at Kigali. These trainers then lead a training of trainers at national level for 177 trainers from district hospital, who in turn trained 2,400 health care providers from district hospitals. Several other tools were also developed concurrently, including the form for reporting poor quality medicinal products, suspected adverse event reporting form, and ADR Alert Card, which have already been printed.

These guidelines for the National Pharmacovigilance System in Rwanda has been developed to complement and support the efforts of educating all health care workers on this important concept and enhance our efforts in ensuring that safe, efficacious and quality medicines are made available to all Rwandans.

Dr. Agnes Binagwaho

Minister of Health

*Kigali, March 2011*
INTRODUCTION

The need for monitoring medicines safety is globally recognized. Pre-marketing clinical trials for the evaluation of quality, efficacy, and safety of new medicines provide the first opportunity for generating data on the safety of a new medicine. However, pre-market clinical trials have many limitations, including the relatively few number of patients exposed and lack of complete understanding of long-term effects, co-morbid conditions, and use in the elderly, children, and pregnant women, and among different racial groups. This means that when a new medicine is released to the public, comprehensive understanding of its safety profile is incomplete.

Additionally, there have been increased efforts recently to expand access and introduce new pharmaceutical products in developing countries. The Government of Rwanda (GoR) has ensured access to these new pharmaceutical products for the management of HIV/AIDS, tuberculosis (TB), and malaria. There is now a great need to compliment the efforts at expanding access with adequate attention to rational use and safety monitoring. Monitoring safety during real-life use can provide valuable safety information to compliment safety data generated during pre-marketing clinical trials.

The need for safety monitoring may be particularly important in resource-constrained countries. Adverse drug reactions (ADR) rank among the top 10 leading causes of mortality in several developed countries;\(^1\) the overall incidence of serious ADRs from 1966 to 1996 was 6.7 percent in the United States and the United Kingdom.\(^2\) The burden of ADRs in Rwanda is unknown; however, it is projected that the burden may even be higher due to several factors including—

- High prevalence of HIV/AIDS, TB, malaria and other co-morbid conditions
- Insufficient knowledge of the quality of pharmaceutical products
- Widespread use of traditional and complimentary medicines
- Different genetic and nutritional status of Rwandese compared to those individuals who participated in the clinical trials
- Lack of capacity to monitor for early signs of toxicity

Pharmacovigilance and medicine information systems are therefore required in Rwanda. Pharmacovigilance can provide useful information when characterizing and quantifying previously recognized ADRs, determining actual effectiveness, identifying, and preventing new drug-induced diseases early on, and reducing mortality and morbidity.

Traditional medicine use is increasing in the Western world (where it is not well regulated) and is widespread in African countries. Several herbal medicines are used frequently, and may be associated with adverse effects. Continuing vigilance is needed.\(^3\)

---

\(^1\) Safety of Medicine - A guide to detecting and reporting adverse drug reaction- why health professionals need to take action. http://apps.who.int/medicinedocs/en/d/Jh2992e/


\(^3\) The Uppsala Monitoring Centre (*the UMC*), WHO Collaborating Centre for International Drug Monitoring. 2000.
The Rwanda Ministry of Health (MoH) is committed to improving medicine safety monitoring and protecting the public health. Guidelines and regulations are in place to ensure that the safety and effectiveness of medicines available in Rwanda are monitored. It is the vision of the MoH that all such related activities should be standardized and coordinated. This *Guideline for Pharmacovigilance and Medicine Information System in Rwanda* provides standard operating procedures (SOPs) and directions for addressing all issues related to medicines and patient safety in a comprehensive manner. Users are encouraged to refer to these guidelines for consistent understanding of medicine safety surveillance activities in Rwanda.

**Establishment of the National Pharmacovigilance and Medicines Information Center**

To address the need for systems for routine medicine safety surveillance and to ensure the protection of public health, the Rwanda MoH has established the National Pharmacovigilance and Medicine Information Center (NPMIC). The NPMIC is based within the National Medicine Regulatory Authority (NMRA) in the MoH. The NPMIC will fulfill its medicine safety role by liaising with numerous MoH units, departments, and committees.

**Overarching Goal of the NPMIC**

NPMIC’s goal is to develop and implement pharmacovigilance and medicine information systems that will provide unbiased information, monitor safety and effectiveness, and improve rational use of pharmaceutical products in Rwanda.

**Scope of Pharmacovigilance and Medicine Information System in Rwanda**

The scope of activities grouped under pharmacovigilance and medicine information undertaken by NPMIC in Rwanda includes the following—

- Monitor safety, effectiveness, and tolerability of medicines used in Rwanda
- Quantify and characterize occurrence of previously recognized ADRs in Rwanda
- Conduct and coordinate spontaneous reporting and active surveillance activities
- Provide unbiased medicine information to health workers and consumers
- Monitor the promotion and advertising of all health products
- Improve rational medicines use
- Contribute to patient safety improvement
- Develop interventions to reduce pharmaceutical product-induced morbidity and mortality

In addition, there are several MoH committees which are responsible for ensuring participation in medicine safety surveillance activities, such as the selection of medicines for inclusion in the standard treatment guidelines or the essential medicine lists. Information on safety, comparative effectiveness, and rational medicines use greatly influence medicine selection activities like the development of standard treatment guidelines, the clinical practice guidelines, and the national essential medicine list. The NPMIC is a national resource in providing evidence-based information to influence medicine selection and related activities of technical committees in Rwanda working in these areas.

**Importance of Pharmacovigilance**

The World Health Organization (WHO) defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. Recently, its concerns have been widened to include——

- Herbal medicines
- Traditional and complementary medicines
- Blood products
- Biologicals
- Medical devices
- Vaccines

The information collected during the pre-marketing phase of drug development is inevitably incomplete with regards to possible ADRs. This is mainly because——

- Tests in animals are insufficiently predictive of human safety
- In clinical trials, patients are selected and limited in number, the conditions of use often differ from those in clinical practice, and the duration of trials is limited
- Information about rare but serious adverse reactions, chronic toxicity, use in specials groups (such as children, the elderly, or pregnant women), or drug interactions is often incomplete or not available

For all medicines, there is a tradeoff between the benefits and the potential for harm. To minimize the harm, it is necessary that medicines of good quality, safety and efficacy are used rationally and that the expectations and concerns of the patient are taken into account when therapeutic decisions are made.

**Importance of Unbiased Medicine Information**

The provision of easily accessible and reliable unbiased information on medicines is an essential element in achieving national health goals in Rwanda. Medicine information service is
committed to provide information to health care professionals, patients, and/or consumers. And will be useful in the following situations—

- Improving care and treatment outcomes
- Ensuring that only evidence-based, consistent, and locally peer-reviewed information are provided to health workers and consumers
- Providing health workers and consumers information on safety of medicines obtained from credible sources
- Educating health workers and consumers through trainings, written materials, and other media activities
- Monitoring medicine promotion and advertising activities to identify and address spurious claims and misinformation
- Conducting comparative effectiveness reviews
- Providing pharmaceutical-related information to other MoH technical committees involved in pharmaceutical products

---

4 U.S. Pharmacopeia. USP DQI Drug Information Program. (program title change, now known as “Promoting the Quality of Medicines”). Available at [http://www.usp.org/worldwide/PQMResourceLibrary.html](http://www.usp.org/worldwide/PQMResourceLibrary.html)
ADVERSE EVENT NOTIFICATION SYSTEM FOR PHARMACOVIGILANCE SYSTEM

An adverse event is any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with the treatment. An adverse drug reaction (ADR) is a response to a medicine which is noxious and unintended, and occurs at a dose normally used in humans for prophylaxis, diagnosis, or therapy of disease; or for the modification of physiological function. This means that any ADR is included in adverse event.

In Rwanda, the notification system will focus on detection of adverse events and the NPMIC and pharmacovigilance subcommittee will conduct causality assessment in order to ensure that this event was really an ADR.

Notification System

NPMIC activities rely heavily in regular interactions with health workers and the patient/consumer. Figure 1 shows the ADR notification system developed to guide the flow of information for all the activities under the scope of pharmacovigilance system. Pharmacovigilance concern or the request for medicine information originates with the patient or consumer. The patient/consumer is at the very foundation of the Rwanda notification system. The patient/consumer can report adverse events and/or requests for medicine information through health centers, private sector clinics and pharmacies, and through hospitals. All adverse events communicated by the patient/consumer will be reported through an adverse event notification form filled in by health care providers and collected by the individual hospital pharmacovigilance subcommittees (which serve as the hub for the implementation of pharmacovigilance activities). The NPMIC has collaborative responsibilities with several bodies including the public health programs and the technical committees (for example, the standard treatment guidelines committees and the pharmaceutical products list committee). The NPMIC reports to the NMRA which is accountable to the MoH.
Figure 1. Notification system for medicine safety surveillance
Roles and Responsibilities in Relation to Pharmacovigilance and Medicine Information

It is important that all stakeholders, consumer organizations, civil societies, and the public have roles in monitoring safety and rational medicines use in Rwanda. The public are therefore encouraged to participate in pharmacovigilance activities through the channels of the notification system. The roles and responsibilities of all bodies listed in the adverse event notification system are listed below.

Patient/Consumer

Patients/consumers have the following roles in medicine safety surveillance in Rwanda—

- If a patient/consumer, family member, or someone the client knows experiences an adverse event occurring during/after any medication or medical intervention, the event should be reported to a health care provider

- Request information from the health care providers within the health facilities or directly from the NPMIC concerning any medicine

- Report any suspicion of poor quality medicine to the community health workers, health centers, hospitals, private clinics, and pharmacies, or directly to the NPMIC

Health Care Providers including Community Health Workers

The health care providers shall provide the best quality care to patients. One of the responsibilities of health care providers is to encourage patients to ask questions about their health condition and to report adverse events. When patients report adverse events, health care providers have to manage and report those adverse events.

Reporting these adverse events will provide valuable national data to be used by technical committees and orient the regulatory decisions. Health care providers have the following roles and responsibilities—

1. Provide advice to the patients on the need to adhere to the treatment plan and to report any adverse event

2. Detect and manage adverse events and all health products-induced disorders

3. Report all adverse events to the NPMIC through pharmacovigilance subcommittees

4. Participate in pharmacovigilance activities in collaboration with the subcommittees

Note: In cases of health products adverse events communicated to community health workers, the workers have the responsibility to refer the patient to the health centre and report the event, if requested.
**PV Subcommittees**

Among the Drug and Therapeutics Committee (DTC) members, a subcommittee shall be appointed to serve on the pharmacovigilance subcommittee. This DTC subcommittee shall implement the policies, guidelines, and standards of the NPMIC. It has the following responsibilities—

- Implement the *Guidelines for Pharmacovigilance and Medicine Information System* in health facilities within its catchment area.
- Ensure the availability of the adverse event notification forms and patient alert cards in health facilities
- Collect, validate, and transmit all notifications to NPMIC
- Ensure that health care providers are trained and familiar with the completion of the notification forms and patient alert cards
- Sensitize health care providers on pharmacovigilance activities
- Collaborate regularly with the NPMIC on pharmacovigilance and medicine information related issues
- Identify and suggest interventions to address any medicine safety and/or irrational use issues in health facilities within their catchment area

**Public Health Programs**

The public health programs (PHPs) are sometimes requested to use new essential medicines. In addition, PHPs which include mass treatment programs, do not have qualified health care providers at community level. In this regards, public health programs are expected to be sensitive to medicine safety issues. The PHPs, therefore, have the following responsibilities—

- Collaborate with NPMIC to identify priority safety issues related to medicines used in their programs
- Collaborate with NPMIC to identify, plan, and conduct active surveillance studies to provide more information on safety issues related to medicines used in the program
- Organize formal reporting of adverse events in mass treatment campaigns
- Help increase awareness on the need to report adverse events for their particular products and their transmission to the NPMIC
• In collaboration with NPMIC, work with the Rwanda National Ethics Committee or related bodies to ensure proper review of study protocols

• Provide findings on all medicine safety-related studies to the NPMIC

• Provide regular feedback to NPMIC on selected medicines safety indicators

• Collaborate with NPMIC to provide regular trainings on pharmacovigilance for health care providers in the PHPs

• Collaborate with NPMIC in using the standard operating procedures (SOPs) and initiating active surveillance of the medicine they managed

**NPMIC**

To fulfill the goal of developing and implementing pharmacovigilance and medicine information system, the NPMIC has the following roles and responsibilities—

• Provide technical advice to the MoH authorities in all policy decisions related to medicine safety in Rwanda

• Provide technical advice to National Medicines Committee (NMC), NMRA, and other related bodies for decision making

• Develop standards and procedures for pharmacovigilance and medicine information activities in Rwanda

• Identify pharmacovigilance and medicine information priorities and lead all efforts in addressing them

• Develop, implement, and update tools for all pharmacovigilance and medicine information activities

• Supervise all relevant pharmacovigilance studies

• Coordinate in-service pharmacovigilance educational activities for health care providers and consumers

• Coordinate and provide technical support to PV subcommittees

• Collaborate with the academic institutions and other stakeholders in providing pre-service trainings in pharmacovigilance

• Provide medicine information to health care providers, patients/consumers, and the entire public through telephone, internet, media, and publications
• Conduct causality assessment of adverse events notifications received

• Serve as the secretariat of the Medicines Safety Committee (MSC)

• Collaborate and participate in regional and international activities related to pharmacovigilance and medicine information, such as active surveillance of people living with HIV under antiretroviral therapy in the Great Lakes region

• Collaborate with the WHO/Uppsala Monitoring Centre (the UMC), and others stakeholders involved in pharmacovigilance and medicine information to exchange information and data with other pharmacovigilance centers

• Establish formal ways of collaboration with all stakeholders in all issues related to pharmacovigilance and medicine information

The NMRA

The NMRA oversees the functioning of the NPMIC and has the following responsibilities—

• Supervise the implementation of the national Guidelines for Pharmacovigilance and Medicine Information System

• Identify knowledge and gaps in pharmacovigilance and collaborate with NPMIC to address them

• Propose to MoH the decisions to be taken to improve medicine safety surveillance and information.

MSC

The MSC serves as an expert advisory committee and is constituted of multidisciplinary specialized persons appointed by the competent MoH authority according to his or her terms of reference.

The MSC has the following responsibilities:—

• Provide technical advice to NPMIC and the NMRA
• Conduct causality assessment on adverse events reports when requested by the NPMIC
• Supervise all post authorization surveillance studies conducted in Rwanda
• Collaborate with the Rwanda National Ethics Committee to approve study protocols

NMC
The NMC proposes decisions on medicines-related issues to the NMRA prior to their approval by MoH authorities. The NMC members shall be appointed by the competent in the MoH Health authority according to his or her terms of reference.

The NMC has the following responsibilities—

- Provide recommendations to the NMRA on decisions and priority interventions to be approved by MoH authority
- Coordinate different medicines safety subcommittees

**Other Stakeholders**

**Marketing Authorization Holder**

Marketing authorization holder s(MAHs) in Rwanda include the holder of the registration certificate, the local representative of the manufacturer (distributor or wholesaler), the importer of the product, and all other persons who obtained permission from the NMRA to manufacture, import, and market pharmaceuticals in Rwanda. Each MAH has the following responsibilities towards medicine safety surveillance in Rwanda—

- Mandatory reporting of all adverse events associated with the product the holder is authorized to distribute, including those events that are not detected in Rwanda. MAHs are responsible to report all such adverse event reports that they are informed of to the NPMIC. Serious adverse events should be reported within 48 hours of the receipt of such reports, while nonserious events should be reported within 15 days of the receipt of the report. The MAH can use the NPMIC notification form for the purposes of this report.

- The MAH is expected to provide all medicine safety relevant information related to his or her authorized product to the NPMIC once every three months.

- The MAH who intends to promote and advertise products or provide sponsorships should adhere to the regulation in place.

- MAHs should collaborate with the NPMIC toward conducting post-authorization safety studies as identified by relevant authorities in Rwanda.

There are many stakeholders that will need to be involved in the national pharmacovigilance and medicine information system at different levels, such as qualified health professionals, researchers and academics institutions, media writers, procurement agencies, standardization institutions, funding and technical assistance partners, and international and regional health organizations.

**UMC/WHO**
The UMC’s responsibilities in regards to the national pharmacovigilance centers, including the NPMIC, are globally the same.

- Receive and store reports from national pharmacovigilance centers
- Provide tools, trainings, and access to information systems to enable national pharmacovigilance centers to search the global WHO database
- Monitor signals from the global WHO database (A signal refers to “reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.”)
- Communicate signal analyses to national pharmacovigilance centers and clinical review of the analyses by experts
- Provide technical assistance to national pharmacovigilance centers
- Facilitate communication between countries
- Develop and maintain WHO Adverse Reaction Terminology and the use of the Medical Dictionary for Regulatory Activities within the WHO International Drug Monitoring Program
- Train national pharmacovigilance centers’ staff
- Standardize procedures relating to pharmacovigilance activities
- Publish relevant documents
- Provide data as appropriate to other parties
MEDICINE INFORMATION

Literature Scan for Relevant Safety Alerts

The NPMIC shall provide unbiased and evidence-based medicines information to health care professionals, consumers, and the public. Appropriate medical literature will be routinely scanned for relevant safety alerts which will then be communicated to stakeholders.

Requesting Medicine Information

Health care professionals, consumers and the public should request medicine information from the NPMIC. Medicine information provided by the NPMIC should be independent and evidence-based. The NPMIC should establish a quality assurance system to ensure that quality medicine information is provided.

Information, Education, Communication Materials, and NPMIC Publications

The NPMIC shall routinely produce relevant information, education, communication materials to meet its objective towards providing quality, relevant, and evidence-based medicine information. The NPMIC shall maintain a regularly publication of medicine information and medicine safety bulletin or newsletter.

Medicine Promotion and Advertising

All medicine promotion and advertising activities shall be conducted with a primary aim of promoting public health and according to the regulations in place. The NPMIC shall notify the competent authority of any medicine promotion and advertising activities that can negatively impact on patient and medicines safety.

The national guidelines for promotion and advertising of pharmaceutical products shall be adapted by the NMRA based on WHO ethical criteria.
PHARMACOVIGILANCE METHODS

The classic pharmacovigilance system relies on—

- Passive surveillance: This applies to the entire population and monitors any adverse events that occur in any patient. Among its weaknesses, there are lack of solid comparisons (target and subject of the surveillance) and the inaccuracy of reporting in addition to the low rate of events occurring. It generates signal/alert that active surveillance could use for further investigations.

- Active surveillance: This method uses the pharmacoepidemiological methods to overcome the limitations of the passive pharmacovigilance. Based on the signal/alert generated by passive surveillance, it helps to identify the subject of surveillance and applies an appropriate methodology that will allow the causality assessment of adverse event. Its main weakness is its high cost in addition to its limited number of subjects.

- MAH surveillance: Once a product is authorized to be on the market, the MAHs are requested to continue to closely monitor their product’s safety to contribute post marketing surveillance. This surveillance combines both passive and active surveillances and it is initiated by the MAHs without any direct participation of the NPMIC.

Passive surveillance is the principal method adapted to limited resources settings like Rwanda. As spontaneous reporting is known as the basic mechanism of this surveillance, it will be the main method to be used in generating signals/alerts of adverse events for further investigations.

Spontaneous Reporting

Spontaneous reporting involves the submission of unsolicited adverse events reports to NPMIC. This is useful for identifying safety signals of rare adverse reactions and generating hypotheses. It provides critical information that is in identifying patients who are at risk of an adverse effect to a medicine. It also can give more information on real-life experience with a medicine beyond data obtained from clinical trials.

Spontaneous reports are usually submitted in a standardized notification forms that includes four key fields—identifiable patient, adverse event, suspected product, and details on the health care professional who produces the adverse event report. Other details, however, must also be reported to help the causality assessment like allergies to medications.

Spontaneous reports can be used for to the reporting of all known and undocumented (unknown) adverse events, serious or not. These events could be the consequences of medication errors, drug interactions, therapeutic ineffectiveness, product quality problems, and problems with

---

medical devices even if there is no obvious relationship between the event and the suspected product. It is important to send spontaneous reports to the NPMIC promptly.

**Spontaneous Reporting in Product Quality Monitoring**

Spontaneous reporting is a routine and cost-effective way of monitoring product quality problems at the national level. A notification form has been developed to allow institutions and health care professionals to alert the Regulatory Authority of problems encountered with the medicines supplied to or used by them. This important information help the safety monitoring of medicines and, in addition to notifying NPMIC, the information goes to other departments in the regulatory authority such as the registration department, inspection department, and the quality control (laboratory analysis) department. The form has been designed to incorporate the most common pharmaceutical problems encountered.

In Rwanda, even though the submission of spontaneous reporting shall be voluntarily done by health care professionals, they are encouraged to report all adverse events brought to their attention. Moreover, it is mandatory to report any serious adverse event which caused—

- Death
- Life threatening conditions
- Disability
- Congenital anomaly
- Hospitalization
- Modification of therapy due to toxicity

The submission of spontaneous reports of suspected adverse events should be guided by the following—

- In-time reporting
  - Report any suspected adverse drug reaction as soon as it occurs

- Accuracy and completeness
  - Each notification form must accurately and legibly be filled out with all the necessary information that is available. This is very important during causality assessment. The minimum information that is required includes—
    - Patient identification
    - Detailed adverse event
    - Details on suspected pharmaceutical product,
    - Identification of the person who is has completed the adverse events notification form

In some emergency cases, reporters can also directly contact the NPMIC to inform them about any adverse event occurred to their premises. The NPMIC will then complete a notification form on their behalf. Reporters are encouraged to have complete information ready at the time they are contacted by NPMIC for more details.
Guidelines for Pharmacovigilance and Medicine Information in Rwanda

- Notification forms—Two notification forms have been developed to capture reporting related to adverse event and poor quality medicines.
  - The notification form for the reporting of all adverse events in patients exposed to a medicine or device in Rwanda is attached to these guidelines (annex A [French]; annex B [English]) and will be available at health facility level. Electronic forms can also be obtained from the MoH website (http://www.moh.gov.rw).
  - The notification form for the reporting all poor quality problems in health facilities or at patient level in Rwanda is attached to these guidelines (annex C [French]; annex D [English]) and will be available to health facilities level. Electronic forms can also be obtained from the MoH website (http://www.moh.gov.rw).

- Emergency cases and lack of forms
  - As mentioned above, in some emergencies, reporters can also directly contact the NPMIC to inform them about any adverse event that occurred on their premises.

Who Should Report?

- All health professionals
- Community health workers
- Patients, patients’ relatives

The Rwanda notification system also allows traditional medicine practitioners and the public at large to report all adverse events related to the use of any health product to the NPMIC through pharmacovigilance subcommittees. Such health products may include complementary and alternative medicine and nutritional and dietary supplements.

Where to Report?

- To health care providers in health facilities
- To pharmacovigilance subcommittee of drug and therapeutics committee in hospital
- To the NPMIC

How to Report Adverse Events

- A patient who has experienced the adverse effect should report to the nearest health care providers.
- The health care providers should fill the notification form and put it in the pharmacovigilance box at their health facilities within the defined time
- At health center level, the head of health center is responsible for collecting the completed adverse effect notification forms in the box and sending them to the hospital management which will forward them to the pharmacovigilance subcommittee
• At the hospital level, the pharmacovigilance subcommittee should appoint one member whose responsibility is to collect all filled notification form from boxes within the hospital.

• The pharmacovigilance subcommittee should validate the collected forms before sending them to the NPMIC within defined period of time

• Once the notification form is submitted and received, there shall be a receipt notification from the receiver.

**How to Report Poor Quality Medicine Problems**

• Any patients, health care professionals, or anyone else who notices/suspects poor medicine quality should report it to the nearest health care providers by—
  - Filling the notification form
  - Reporting the poor quality to a health care provider by any other mean than notification

• The health care providers who made the notification or receive it should put it in the PV box at their health facilities within the defined time

• At health center level, the head of health center is responsible of collecting the filled poor quality medicine notification form in the PV box and sending it to the hospital management which will orient them to the PV subcommittee

• At the hospital level, the PV subcommittee should appoint one member who is responsible to collect all filled notification form from PV boxes within the hospital.

• The PV subcommittee should validate the collected forms before sending them to the NPMIC within defined period of time

**What Should Be Reported?**

• Report all suspected adverse events to medicines, traditional/herbal medicines, X-ray contrast media, medical devices, cosmetics, nutritional and dietary supplements, and other health products which are not mentioned here.

• In addition to the ADR, report medicine quality problems noticed at patient level such as—
  - Color change
  - Separation of components
  - Powdering/crumbling
  - Caking
  - Molding
  - Change in smell
  - Poor packaging
  - Poor labeling and mislabeling
  - Suspected contamination
Guidelines for Pharmacovigilance and Medicine Information in Rwanda

- Questionable stability
- Defective components
- Expired medicines

**When to Report?**

- Serious adverse events should be reported immediately to the NPMIC or its decentralized unit as they occur or as the reporter learnt about them. When those reports are sent to the PV subcommittees, those units are requested to transmit them to the NPMIC without any delay.

- The notification form for serious adverse events must be filled within 24 hours and sent to the NPMIC within 48 hours from the time of notification.

- Serious adverse events must be reported to the head of clinical services before being sent to the NPMIC.

- Other adverse events reports should be received at NPMIC no later than one month after they have been reported to the health facility.

- Poor medicine quality should be reported as soon as possible, it follow the same scheme as the other adverse events.

**What Happens to a Report?**

- The submitted report will be validated and entered into the national database of adverse events. This database enables the NPMIC to keep track of all adverse event reports received nationwide.

  - For adverse event, the reports are routinely analyzed using WHO method as they are received and documented in a standard format for the determination of causality by the NPMIC.

  - For poor medicine quality, the reports are analyzed by a team composed by representatives of the Medicine Inspection Desk, Medicine Registration Desk, NPMIC staff, Rwanda Bureau of Standard, and laboratory of medicine analysis.

- The information obtained from these analyses will be submitted to the NMRA to enable the MoH for decision making. NPMIC will disseminate conclusions from analysis report and related decisions through existing communication channels.

- The NPMIC will regularly send—

  - Analyzed adverse event notifications to the UMC
  - Analyzed notification of poor medicine quality to inspection, registration, and lab analysis department for further actions
Pharmacovigilance Methods

- A well-completed and duly submitted adverse events and poor medicine quality notification form by a health professional may result in—
  - Additional investigations into the use of the medicine in Rwanda
  - Appropriate changes in the package insert
  - Changes in the ways of using the pharmaceutical product
  - Enhancing educational initiatives to improve the safe use of that medicine
  - Other regulatory and health promotion interventions as the situation may warrant including product withdrawal/recall

**How Do the Health Care Provider and Patient Benefit from Reporting?**

The health care provider and patient benefit from reporting through—

- Improved quality of care offered to patients
- Reduced medicine-related problems leading to better treatment outcome
- Improved patient confidence in professional practice, hence professional growth
- Improved knowledge
- Access to feedback information on medicine-related problems reported within the country and internationally
- Satisfaction in fulfilling a moral and professional obligation

**Use of Spontaneous Reporting in Medication Error and Patient Safety Monitoring**

The notification form in Rwanda contains fields for the documentation of medication errors occurred simultaneously with an adverse event. The NPMIC shall monitor medication errors and assess their root causes to contribute in improving patient care. The NPMIC will use an updated version of the US National Coordinating Council for Medication Error Reporting and Prevention index for categorizing medication errors.

**Protection of the Health Care Professionals Who Report Adverse Events**

- Reporting an adverse event does not necessarily mean that the health care professional or the drug has contributed to or caused it.

- The outcome of the notified adverse event will be communicated to the health care provider who reported the case.

- The information given in the notification form is strictly confidential up to the central database level.

- The information obtained from reports will not be used for commercial purposes, but is intended to improve the understanding of using pharmaceutical products.

**Active Surveillance**
The spontaneous reporting system remains the backbone of medicine safety monitoring in Rwanda. Active surveillance methods can be used in further validating spontaneous report signals generated through the NPMIC spontaneous notification system. However, because of the known limitations of spontaneous reporting including the lack of denominator data, lack of controls, poor case documentation, and the inability to ascertain the report’s validity, the NPMIC should promote conducting relevant active surveillance studies in Rwanda. The overall responsibility for the monitoring of active surveillance studies and other pharmacoepidemiology studies remain the prerogative of NPMIC.

**Some Active Surveillance Methods to be Used in Rwanda**

To implement plans for routine active surveillance activities, the NMRA will ensure that SOPs are in place for conducting active surveillance studies. After identifying research priorities, the authority will provide technical guidance on the preferred active surveillance method to be used. The following active surveillance methods can be used—

- Cohort event monitoring
- Case control studies
- Prescription event monitoring
- Medicine/device exposure registries
- Medicine utilization studies

The PHPs can identify their research priorities based on prevalence, frequency, and importance of ADR spontaneous reports related to their specific products. They should therefore regularly collaborate with the NPMIC and identify important signals that may require validation using active surveillance methods.


SAFETY MONITORING OF HERBAL MEDICINES IN THE NATIONAL PHARMACOVIGILANCE SYSTEM

In developing countries, some herbal medicines are considered to be more readily available, accessible, affordable, culturally acceptable and sustainable than Western medicines. In developed countries, the popularity of herbal medicines continues to grow, particularly for treating certain disease categories.

However, herbal medicines are not necessarily always safe simply because they are natural. Some have given rise to serious adverse reactions and some contain chemicals that may produce long-term side effects such as carcinogenicity and hepatotoxicity. Herbal medicines will only benefit the health of human beings when they are used appropriately. Thus, good quality control and standardization of herbal medicines are essential. Furthermore, with the increased use of both herbal medicines and modern western pharmaceutical drugs, there is a need to monitor interactions.

Reporting adverse events related to herbal medicines shall be the same as for the other health products mentioned in this guideline and shall involve cooperatives made up of traditional healers that are officially approved by the appropriate authorities.

The national policy on traditional and herbal medicine as well as related guidelines shall be the referral and support documents.
TOOLS FOR MEDICINE SAFETY SURVEILLANCE ACTIVITIES

Pharmacovigilance activities involve the use of several validated tools to generate and analyze data to guide decisions. In an effort to standardize all pharmacovigilance and medicine information system processes in Rwanda, the following tools have been developed and adopted for key activities of the NPMIC.

Adverse Event Notification Form

The Adverse Event Notification Form (annex A–French; annex B–English) is the official tool by which all suspected adverse events shall be reported. It is designed to be short, simple, and easy to complete. The notification form collects important details pertaining to the suspected adverse events. The form should be used for the following events—

- All suspected adverse events related to the use of medicines and medical devices
- All suspected adverse events related to the use of complementary and alternative medicines, traditional/herbal medicines, and cosmetics, nutritional and dietary supplements

Medicine Information Request Form

The medicine information request form (annex E) is the official tool in Rwanda for making requests to the NPMIC for information related to medicines or health products and related pharmacotherapy issues. The scope of what can be included in a request for medicine information includes—

- Mode of administration and dosage
- Indication and choice of therapy
- Interactions (drug-drug, drug-disease, etc.)
- Adverse effects and toxicities
- Management of poisoning
- Product identification, packaging, labeling
- Product manufacturer and availability
- Medicine utilization data
- Disease profile and management
- Recent evidence and studies on specific diseases and medicines
- Epidemiology of diseases in Rwanda
- Any other related questions

Requesting for medicine information can also be through phone calls and e-mail messages. Clients are requested to clearly specify what information they seek so that they can receive answers that precisely answer their questions. The NPMIC has developed standard tools for providing responses to the enquirer.
Causality Assessment Tool

After adverse event reports are received, the NPMIC works closely with the MSC to determine causality between the reported event and the health products the patient or consumer would have been exposed to. There are several scales for determination of causality. In Rwanda, the NPMIC will use the WHO causality assessment criteria as the official reference for deciding on the contribution of the health product to the adverse event. The criteria are classified as Certain, Probable/Likely, Possible, Unlikely, inaccessible/unclassified, and conditional/unclassified. The WHO causality assessment criteria tool is attached as annex F.

Adverse Event Severity Grading Scale

When adverse events are reported in Rwanda, the severity of the event will be determined through an evaluation of the report, medical records, and further discussions with the reporter. Understanding of the severity of adverse events will guide the decisions about adverse events that are of importance for further studies in Rwanda. It will also provide information for the education of health care workers on adverse events and their management. In Rwanda, the WHO Toxicity Grading Scale for determining the severity of adverse events will be the official reference for the grading of severity of adverse events. The tool is attached as annex G.

Medication Error Assessment Tool

When medication errors are identified and reported, there are opportunities for learning from the experience and preventing further errors. The NPMIC provides advocacy and resources for the monitoring and learning from medication errors and patient safety problems. In Rwanda, the American National Coordinating Council for Medication Error Reporting and Prevention Index, (NCC MERP) will be the official reference for grading medication errors in Rwanda. The NCC MERP index is attached as annex H.

Patient Alert Card

The Patient Alert Card notifies all health care providers that its bearer has experienced some serious intolerance (typically hypersensitivity reactions) to a particular medicine. This will help them to identify the patient's drug-related intolerance and prevent the same (or similar) drug reactions. The card is expected to be carried by the patient all the time and must be presented to health care providers during consultation or dispensing time. The Patient Alert Card for official use in Rwanda is attached as annex I (annex J is Patient Alert Card in Kinyarwanda). This card will be delivered by PV subcommittee and inform NPMIC for registration.

Glossary of Medicine Safety Terms
To ensure common understanding of all terms used in medicine safety surveillance activities in Rwanda, standard official definitions as applicable to Rwanda have been provided for relevant pharmacovigilance and medicine safety terminologies. Users are encouraged to review these terms and use them in the same definition and meaning as it has been provided in this document. The official glossary of medicine safety terms are provided as annex K.

All health care workers are encouraged to use these tools as indicated and continuously provide positive criticisms on their improvement to the NPMIC. The NPMIC, in consultation with various stakeholders, will review these guidelines and tools periodically, to ensure that they continue to meet the goals of pharmacovigilance and medicine information activities in Rwanda.
CAPACITY BUILDING

Staff members working at health facilities require continuous capacity building activities on pharmacovigilance. ADRs are not well understood and, in many countries, are seldom detected. Attention to monitoring also may be neglected, and thus staff members need to stay aware that ADR monitoring is part of their good clinical practices. Trainings are required to ensure that staff members understand prescribing practices for new medicines, the correct dosage regimen, and how treatment failures are managed. Staff members also need to be taught how to detect ADRs, where to refer the patients, and how to complete the ADR reporting form accurately. In addition, continuous clinical guidance for improved recognition of adverse reactions is required. Staff will need to feel confident and motivated in reporting while assisting the NPMIC in its mission. Common concerns and barriers to reporting by health care personnel will be addressed in such capacity building activities.

The MoH, through technical assistance of SPS, has developed the National Curriculum and Training Module for pharmacovigilance. The purpose of this training is to equip all health care workers across the health care delivery system with the necessary skills, knowledge, and attitudes that will enable them to effectively identify, assess, and report ADRs; and take appropriate action to improve medicine safety. The trainings will start with a training of trainers limited to a small number of health care providers, essentially doctors and pharmacists, who will be subsequently called upon to conduct the national training for selected DTC members at the hospital level. With the support of training of trainers’ core group, NPMIC will supervise service trainings throughout the country at district level, using the trained DTC members as trainers in their respective health facilities.

The NPMIC will routinely coordinate any other capacity building activities at national and hospital level to ensure the correctness and relevance of the delivered information while avoiding unnecessary dispersion of efforts.
MONITORING AND EVALUATION

For effective pharmacovigilance and medicine information activities in Rwanda, the NMRA shall identify some performance measures for monitoring pharmacovigilance activities of both NPMIC and the PHPs. These performance measures include indicators, reports, and performance targets that will be routinely reported to the NMRA.
# Annex A. Adverse Event Notification Form (French)

---

**Annexe A. Fiche de notification des événements indésirables**

## A. Informations sur le patient

<table>
<thead>
<tr>
<th>Informations sur le patient</th>
<th>Voir ci-dessous...</th>
<th>Date de naissance...</th>
</tr>
</thead>
<tbody>
<tr>
<td>N° d'identification du patient</td>
<td>Délai d'apparition de la réaction (en heures/jours)</td>
<td>Date et heure d'arrêt de réaction si applicable</td>
</tr>
<tr>
<td>Poids (Kg)</td>
<td>Taille (en cm)</td>
<td>Sexe</td>
</tr>
<tr>
<td>Date de fabrication</td>
<td>Date d'expiration</td>
<td>No de Lot/batch N°</td>
</tr>
</tbody>
</table>

**Centre National de Pharmacovigilance et d'Information Pharmaceutique**

**Fiche de notification des événements indésirables**

---

**B. Informations sur les événements indésirables susceptibles d'être dus au produit de santé**

<table>
<thead>
<tr>
<th>Description de l'événement indésirable</th>
<th>Voir ci-dessous...</th>
<th>Date et heure de début de réaction...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Délai d'apparition de la réaction</td>
<td>Date et heure d'arrêt de réaction si applicable</td>
<td>Date et heure d'arrêt de réaction si applicable</td>
</tr>
</tbody>
</table>

**INFORMATION SUR LE PRODUIT DE SANTE SUSPECTE**

<table>
<thead>
<tr>
<th>Nom du produit en DCI ou nom vernaculaire, forme et dosage</th>
<th>Date de fabrication</th>
<th>Date d'expiration</th>
<th>No de Lot/batch N°</th>
</tr>
</thead>
</table>

---

**Republique du RWANDA**

MINISTERE DE LA SANTE
C. Autres produits utilisés

Y a-t-il d’autres produits utilisés par le patient ? □ Oui □ Non
Si oui compléter le tableau ci-dessous
(Ajouter une feuille supplémentaire si nécessaire)

<table>
<thead>
<tr>
<th>Nom du produit</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posologie utilisée par le patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voie d’administration telle que utilisée par le patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date (et si possible heure) de début</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date (et si possible heure) d’arrêt</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. Informations sur le notificateur

| Nom et Prénom * |   |
| Qualification * : | Lieu de travail /FOSA* |
| Adresse postale* : | Téléphone du lieu de travail /FOSA * |
| Email : | Date* |

Votre appui au système de pharmacovigilance est grandement apprécié.

La soumission d’une plainte n’implique en aucun cas que le médicament ou le prestataire des soins ont causé ou contribué à l’apparition de cet événement. Toute information est strictement confidentielle et le personnel du système de pharmacovigilance ne mettra jamais en public l’identité du rapporteur en réponse à une quelconque demande publique.

L’information que vous fournissez contribuera dans l’amélioration de la qualité des soins et la sécurité d’utilisation du médicament.

Une fois remplie, veuillez envoyer cette fiche au Centre National de Pharmacovigilance ou au sous comité de Pharmacovigilance dans l’hôpital qui vous est proche

Que peut vous apporter le CNPIP ?

Le CNPIP est au service de tous les professionnels de santé tant du secteur public que privé pour :

- Recueillir et analyser toute suspicion suggérant un effet indésirable dû à un produit de santé afin d’établir la relation de cause à effet
- Répondre aux questions relatives à l’utilisation des produits de santé
- Évaluer les risques d’une exposition aux produits de santé chez les personnes à haut risque
- Diffuser les informations sur la pharmacovigilance aux professionnels de la santé, aux patients/consommateurs et au grand public

Notification des effets indésirables au CNPIP

La pharmacovigilance a pour objet la détection, l’évaluation et la prévention des effets indésirables de tout produit de santé survenant dans une population.

Les produits de santé concernés par cette notification sont :

- Les produits pharmaceutiques
- Le sang et ses dérivés
- Autres produits de santé notamment les produits alimentaires et cosmétiques, ainsi que les produits biologiques tels que les cellules humaines, les tissus, et les produits à base de cellules ou de tissus.
Qui doit notifier?
- Tous les professionnels de santé

Que faut-il notifier ?
- Tout événement indésirable, clinique ou biologique, observé chez un patient et coïncidant avec l’exposition à un produit de santé, connu ou non connu, grave ou bénin.

Comment notifier ?
- La notification du cas doit se faire sur cette « fiche de notification des effets indésirables » du Ministère de la Santé.
- La notification du cas peut se faire par :
  o Courrier : BP 84 Kigali
  o Téléphone : 114
  o Personne de contact : Ruzindaza Alexis
  o E-mail : ptfmoh@yahoo.fr
  o Site web : www.moh.gov.rw

Veuillez noter que :
- La notification du cas se fait même si vous n’êtes pas sûrs que ce soit le produit suspecté qui est à la base de l’effet indésirable ou quand vous n’avez pas suffisamment de données.
- La soumission d’une fiche de notification n’implique pas automatiquement que le professionnel de santé ou le produit a causé ou contribue à l’apparition de l’effet indésirable
- La fiche de notification remplie doit être acheminée vers le niveau supérieur endéans 48 heures
- Toutes les informations rapportées sur cette Fiche sont **strictement confidentielles**.
- Les informations sur le notificateur qui sont accompagné du signe * sont obligatoire
- Pour les sites ART, le dispensateur des soins identifiera le patient par son code TRACNET.
ANNEX B. ADVERSE EVENT NOTIFICATION FORM (ENGLISH)

National Center for Pharmacovigilance and Medicine Information
Adverse Event Notification Form

A. Patient Information

<table>
<thead>
<tr>
<th>Patient address</th>
<th>Village :</th>
<th>Sector:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell :</td>
<td>District:</td>
<td></td>
</tr>
</tbody>
</table>

Other available address (cell phone/email, ….)

<table>
<thead>
<tr>
<th>No. of patient file/dossier</th>
<th>Date of birth or age</th>
<th>weight (Kg)</th>
<th>height (cm)</th>
<th>Sex □ F □ M</th>
</tr>
</thead>
</table>

Pregnancy? □ Yes □ No □ Don’t know
If yes, indicate the length of pregnancy in weeks (amenorrhea weeks):

The pregnant woman is: □ primiparous □ multiparous

Does the patient have any chronic diseases? □ Yes □ No □ Don’t know
If yes, list those diseases (diabetes, tuberculosis) in the following areas (you can add another paper if needed):

1

Associate risk factors (tick on the following ones): tobacco use, alcohol use, clinical background, familial history, allergies …
Describe any other risk factors if applicable (you can add a new paper on this if needed):

B. Information on adverse events related to suspected health product

Description of the adverse event:

Date and time when adverse reaction started: …/……/…… at ……..h….. min
Time to onset of reaction (hours/days): ……………………
Date and time when reaction stopped: …/……/…… at ……..h…..min

INFORMATION ON THE SUSPECTED HEALTH PRODUCT

Name of the product en INN or local name (if plant medicine), form and dosage:
Brand name/manufacturer:

Manufacture date: Expired date: Batch No.:

The product was prescribed? □ Yes □ No
If the product was prescribed, indicate the reason why:

Dosage Prescribed: Frequency of daily dosing prescribed: Treatment duration
Dosage taken: Frequency of daily dosing use by patient:

Date, if possible, the time of the starting taking the suspected product:
Date, if possible, the time the suspected product was stopped:

The administration route used by patient:
Details on the dilution (if applicable):

Where patient has been provided with this product?
Is it the first time the patient has taken the suspected product? □ yes □ No If no, did he experiment the same reactions the last time he take this product □ yes □ No

Is there any measure taken to manage /treat this adverse event? □ yes □ No
If yes, indicate these measures (pharmaco-therapy, refer the patient, stop the treatment, change the treatment, etc....)

Evolution of adverse event
☐ Recovery without sequelae  ☐ Hospitalization  ☐ Life threatening  ☐ Deceased  ☐ others : specify
☐ Not recovery  ☐ hospitalization prolonged  ☐ Permanent incapacity  ☐ Unknown

C. Other product used: Is there any other product used by patient? □ Yes □ No If yes, fill the table below
(Add a new page if needed)

<table>
<thead>
<tr>
<th>Name of the Product</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage used by patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration route used by patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date (time if applicable ) of start to take the product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date (time if applicable) of stop to take the product</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. Information on the notificator

<table>
<thead>
<tr>
<th>Name *</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Qualification * :</td>
<td>Place of Works/Health Facility*</td>
</tr>
<tr>
<td>PO box* :</td>
<td>Phone number/yours or for the Health Facility*</td>
</tr>
<tr>
<td>Email :</td>
<td>Date*</td>
</tr>
</tbody>
</table>

Your support in this pharmacovigilance program is appreciated.

Submission of a complaint does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to an event.

All information is held in strict confidence and programme staff is not expected to and will not disclose reporter’s identity in response to any public request. Information supplied by you will contribute to the improvement of medicine safety and therapy in Rwanda.

Once completed please send to: National Pharmacovigilance and Medicine Information Center or to the Drug and Therapeutic Committee (DTC) of the hospital which is near of you.
# Annex C. Poor Medicine Quality Notification Form (French)

## Centre National de Pharmacovigilance et d'Information Pharmaceutique

### Fiche de Notification sur la Qualité des Médicaments

## A. Informations sur le rapporteur

<table>
<thead>
<tr>
<th></th>
<th>Veuillez cochez dans la case suivante votre</th>
<th>1. patient</th>
<th>2. Professionnel de la santé</th>
<th>3. autres : spécifier :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adresse du rapporteur</td>
<td>Village :</td>
<td>Secteur</td>
<td>Cellule :</td>
</tr>
<tr>
<td></td>
<td>Autres adresses disponibles (téléphone/email, lieux de travail etc…)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Le rapporteur a-t-il pris le médicament</td>
<td>☐ Oui ☐ Non</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## B. Identification du produit

<table>
<thead>
<tr>
<th>Nom de spécialité</th>
<th>Non générique</th>
<th>Numéro de lot</th>
<th>Date de fabrication</th>
<th>Date de péremption</th>
<th>Date d’acquisition/achat</th>
<th>Nom du producteur et son pays d’origine</th>
<th>Adresse du distributeur</th>
</tr>
</thead>
<tbody>
<tr>
<td>FORMULATION DU PRODUIT (cocher sur le cas échéant)</td>
<td>PLAINTES A L’ENCONTRE DU PRODUIT (cochez sur le cas échéant)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprimé Oral/Capsule</td>
<td>Hangement de couleur</td>
<td>gglomération/ grumeaux</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suspension buvable</td>
<td>isqueux (formes solides)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goutte Oculaire</td>
<td>Hangement d’odeur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goutte nasale</td>
<td>Réparation des composants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solution nébulisante</td>
<td>Friètement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crème/ gel/pommade</td>
<td>Jauvaise étiquetage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autres :…………………………………………………………………………</td>
<td>Conditionnement incomplet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Décrivez en détail votre plainte…………………………………………………………………………………………………………………………………………… |
|………………………………………………………………………………………………………………………………………………………………… |
|………………………………………………………………………………………………………………………………………………………………… |
|………………………………………………………………………………………………………………………………………………………………… |
|………………………………………………………………………………………………………………………………………………………………… |

## C. Condition de stockage

<table>
<thead>
<tr>
<th></th>
<th>Le produit requiert il une réfrigération ?</th>
<th>☐ oui ☐ non</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Le produit est-il disponible à la Formation Sanitaire ?</td>
<td>☐ oui ☐ non</td>
</tr>
<tr>
<td></td>
<td>Le produit est-il retournée par le patient après qu’il ait été dispensé</td>
<td>☐ oui ☐ non</td>
</tr>
<tr>
<td></td>
<td>La conservation/stockage du produit est elle conforme aux directives du producteur ou du MINISANTE</td>
<td>☐ oui ☐ non</td>
</tr>
</tbody>
</table>
D. Circonstance et moment de detection du probleme de la qualite du produit

<table>
<thead>
<tr>
<th>A quel moment avez-vous constaté que le medicament avait un problème de qualité</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avant la prise du medicament</td>
</tr>
<tr>
<td>Au cours de la prise du medicament</td>
</tr>
<tr>
<td>A la fin de la prise du medicament</td>
</tr>
<tr>
<td>Quand un proche (parent ou ami(e)) a pris ce medicament</td>
</tr>
<tr>
<td>Quand un patient que vous traitez/suivez a pris ce medicament</td>
</tr>
<tr>
<td>Autres : specifiez...</td>
</tr>
</tbody>
</table>

Dans quelle circonstance avez-vous constaté ce problème de qualité?

- A la suite d’une complication de l’état d’un patient/ami(e)/parent après la prise du medicament
- La suite d’une hospitalisation du patient après la prise du medicament
- La suite d’une plainte du patient
- La suite d’un constat personnel dans le lieu de stockage du medicament

Si vous ou quelqu’un d’autres aviez déjà pris ce medicament avez-vous constaté des symptômes/signes cliniques suspects ?

Oui [ ] Non [ ]

Si oui veuillez remplir la fiche de notification des événements indésirables.

Votre appui au système de pharmacovigilance est grandement apprécié.

La soumission d’une plainte n’implique en aucun cas que le médicament ou le prestataire des soins ont causé ou contribué à l’apparition de cet événement. Toute information est strictement confidentielle et le personnel du système de pharmacovigilance ne mettra jamais en public l’identité du rapporteur en réponse à une quelconque demande publique.

L’information que vous fournissez contribuera dans l’amélioration de la qualité des soins et la sécurité d’utilisation du médicament. Une fois remplie, veuillez envoyer cette fiche au Centre National de Pharmacovigilance ou au sous comité de Pharmacovigilance dans l’hôpital où vous est proche.
### A. Information on the notificator

<table>
<thead>
<tr>
<th>Address of notificator</th>
<th>Village:</th>
<th>Sector</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cell:</td>
<td>District</td>
</tr>
</tbody>
</table>

Has the person who made the notification come in direct contact with the reported product? □ Yes □ No

### B. Product identity

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch/lot number</td>
<td>Date of manufacture</td>
</tr>
<tr>
<td>Date of receipt</td>
<td>Name of manufacturer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of distributor/supplier</th>
<th>Distributor/supplier’s address</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PRODUCT FORMULATION (tick appropriate box)</th>
<th>COMPLAINT (tick appropriate box/boxes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Oral tablet/capsule</td>
<td>□ Colour change</td>
</tr>
<tr>
<td>□ Oral suspension/syrup</td>
<td>□ Separating</td>
</tr>
<tr>
<td>□ Injection</td>
<td>□ Powdering/crumbling</td>
</tr>
<tr>
<td>□ Diluent</td>
<td>□ Caking</td>
</tr>
<tr>
<td>□ Powder for reconstitution of suspension</td>
<td>□ Moulding</td>
</tr>
<tr>
<td>□ Powder for reconstitution of injection</td>
<td>□ Change of odour</td>
</tr>
<tr>
<td>□ Eye drop</td>
<td>□ Mislabelling</td>
</tr>
<tr>
<td>□ Ear drop</td>
<td>□ Incomplete pack</td>
</tr>
<tr>
<td>□ Nebuliser solution</td>
<td>□ Other:</td>
</tr>
<tr>
<td>□ Cream/ointment/liniment/paste</td>
<td>...........................................</td>
</tr>
<tr>
<td>□ Other:</td>
<td>...........................................</td>
</tr>
</tbody>
</table>

Describe complaint in detail: ................................................................. ................................................................. ................................................................. ................................................................. ................................................................. .................................................................

### C. Storage conditions

<table>
<thead>
<tr>
<th>Does the product require refrigeration?</th>
<th>Yes</th>
<th>No</th>
<th>Others details (if necessary):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was the product available at facility?</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Was product dispensed and returned by client?</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Was the product stored according to manufacturer/MoH recommendations</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

### D. Circumstance and time of poor quality detection
At which time did you notice that the poor quality problem?
- Before taking the product
- While I took the product
- After I took the product
- When relatives took the product
- When my patient took this product
- Other…………………………………………………………

In which circumstance did you notice the poor quality problem?
- When I notice complication of my patient/relatives after he or she took this product
- When a patient was hospitalized after taking this product
- After a complaint of patient who is under this medication
- After personally observing experience the poor quality of this medicines in the storage room

Have you experienced any adverse event or did you receive any complaint after taking this medicine?
Yes ☐ No ☐

If you, or any other person has already take this medicine and experienced any health problem, please complete the adverse event notification form.

Your support in this pharmacovigilance program is appreciated.
Submission of a complaint does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to an event.

All information is held in strict confidence and programme staff will not disclose reporter’s identity in response to any public request. Information supplied by you will contribute to the improvement of medicine safety and therapy in Rwanda.

Once completed, please send to: National Pharmacovigilance and Medicine Information Center or to the Drug and Therapeutic Committee (DTC) of the hospital which is nearest you.
## ANNEX E. MEDICINE INFORMATION REQUEST FORM

<table>
<thead>
<tr>
<th>Date:</th>
<th>Time Received:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received by:</td>
<td></td>
</tr>
</tbody>
</table>

### Name of Requester:

<table>
<thead>
<tr>
<th>Requester Identity:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Patient</td>
<td></td>
</tr>
<tr>
<td>□ Pharmacist</td>
<td></td>
</tr>
<tr>
<td>□ Physician</td>
<td></td>
</tr>
<tr>
<td>□ Nurse</td>
<td></td>
</tr>
<tr>
<td>□ Other (specify)</td>
<td></td>
</tr>
</tbody>
</table>

### Preferred method of delivery:

<table>
<thead>
<tr>
<th>Phone</th>
<th>Fax</th>
<th>Email</th>
<th>Mail</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

### References required:

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

### Contact information

<table>
<thead>
<tr>
<th>Phone number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fax number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email address:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mailing address:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

### Response needed/given in:

<table>
<thead>
<tr>
<th>Instantly</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

| 10 min |
| □      |

| 30-60 min |
| □        |

| End of day |
| □         |

<table>
<thead>
<tr>
<th>When time permits</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

### Summary of the question

### Pertinent Background Information (if possible, provide more details on the chosen information)

<table>
<thead>
<tr>
<th>Known allergy:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chronic illnesses:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pregnancy:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Breastfeeding:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Concurrent medications:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

### Type of Request:

<table>
<thead>
<tr>
<th>Indication/choice of therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Therapeutics Alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contra-indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Precautions to be taken while on treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adverse Drug Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interactions (Drug-drug/drug-disease/drug-food)</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine Identification/Packaging/Labeling</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

### Search Strategy:

<table>
<thead>
<tr>
<th>Consultation of other colleagues</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consultation of specialists</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Documentation in a book/article/journal</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Internet documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Others (please specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

### Response given:

### References:
ANNEX F. WHO CAUSALITY ASSESSMENT CRITERIA

Causality assessment criteria

1. Certain:
   - Clinical event, including laboratory test abnormality, occurring in a plausible time relationship to drug administration, and which
   - Cannot be explained by concurrent disease or other drugs or chemicals.
   - Response to withdrawal of the drug (challenge) should be clinically plausible.
   - Event must be definitive pharmacologically or pharmacologically, using a satisfactory challenge procedure if necessary.

2. Probable/Likely:
   - Clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug
   - Unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal (challenge)
   - Rechallenge information is not required to fulfill this definition.

3. Possible:
   - Clinical event, including laboratory test abnormality, with a reasonable time sequence to administrations of the drug, but which
   - Could also be explained by concurrent disease or other drugs or chemicals
   - Information on drug withdrawal may be lacking or unclear.

4. Unlikely:
   - Clinical event, including laboratory test abnormality, with a temporal relationship to drug administration which makes a causal relationship improbable, and in which
   - Other drugs, chemicals or underlying disease provide plausible explanations.

5. Conditional/Unclassified:
   - Clinical event, including laboratory test abnormality, reported as an adverse reaction, about which
   - More data is essential for a proper assessment, or the additional data is under examination.

6. Unassessable/Unclassifiable:
   - Report suggesting an adverse reaction which
   - Cannot be judged because information is insufficient or contradictory, and which
   - Cannot be supplemented or verified.

---

1 WHO Causality categories in WHO (2000) Safety Monitoring of Medicinal Products: Guidelines for setting up and running a Pharmacovigilance Centre, the Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring, ISBN 91-630-9004-X
# Annex G. WHO Toxicity Grading Scale

## Who Toxicity Grading Scale for Determining the Severity of Adverse Events

<table>
<thead>
<tr>
<th>CHEMISTRIES (continued)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperglycaemia</td>
<td>116 - 160 mg/dL</td>
<td>161 - 250 mg/dL</td>
<td>251 - 500 mg/dL</td>
<td>&gt; 500 mg/dL</td>
<td></td>
</tr>
<tr>
<td>(note if fasting)</td>
<td></td>
<td></td>
<td></td>
<td>ketosis/diabetes</td>
<td>or seizures</td>
</tr>
<tr>
<td>Hypocalcaemia (corrected</td>
<td>8.4 - 7.8 mg/dL</td>
<td>7.7 - 7.0 mg/dL</td>
<td>6.9 - 6.1 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
<td></td>
</tr>
<tr>
<td>for albumin)</td>
<td></td>
<td></td>
<td></td>
<td>or life-threatening</td>
<td>arrhythmia/</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>arrhythmia/</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>tetany</td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia (correct</td>
<td>10.6 - 11.5 mg/dL</td>
<td>11.6 - 12.5 mg/dL</td>
<td>12.6 - 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
<td></td>
</tr>
<tr>
<td>for albumin)</td>
<td></td>
<td></td>
<td></td>
<td>life-threatening</td>
<td>arrhythmia</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>1.4 - 1.2 mEq/L</td>
<td>1.1 - 0.9 mEq/L</td>
<td>0.8 - 0.6 mEq/L</td>
<td>&lt; 0.6 mEq/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>or life-threatening</td>
<td>arrhythmia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>2.0 - 2.4 mg/dL</td>
<td>1.5 - 1.9 mg/dL</td>
<td>1.0 - 1.4 mg/dL</td>
<td>&lt; 1.0 mg/dL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>replacement Rx</td>
<td>intensive Rx</td>
<td>or life-threatening</td>
<td>arrhythmia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>required</td>
<td>or hospitalization</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>1.1 - 1.5 x ULN</td>
<td>1.6 - 2.5 x ULN</td>
<td>2.6 - 5 x ULN</td>
<td>&gt; 5 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUN</td>
<td>1.25 - 2.5 x ULN</td>
<td>2.6 - 5 x ULN</td>
<td>5.1 - 10 x ULN</td>
<td>&gt; 10 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>1.1 x 1.5 x ULN</td>
<td>1.6 - 3.0 x ULN</td>
<td>3.1 - 6 x ULN</td>
<td>&gt; 6 x ULN or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>required dialysis</td>
<td></td>
</tr>
</tbody>
</table>

## Urinalysis

| Proteinuria             | 1+ or < 0.3% or <3g/L | 2-3 or 0.3 - 1.0% or 3-10 g/L | 4+ or > 1.0% or > 10 g/L | nephrotic syndrome or > 3.5 gm loss/day |
|                        | or 200 mg - 1 gm loss/day| 1-2 gm loss/day | 2-3.5 gm loss/day |                  |
| Hematuria               | microscopic only       | gross, no clots    | gross+ clots     | obstructive or   |
|                         |                        |                   |                  | required transfusion|

## Cardiac Dysfunction

| Cardiac Rhythm          | asymptomatic, transient signs, no Rx required | recurrent/persistent; No Rx required | requires treatment |
|                        |                                              |                                   |
| Hypertension            | transient inc. > 20 mm; no Rx               | recurrent, chronic, > 20 mm, Rx required | requires acute Rx; No |
|                         |                                              | hospitalization                   |
| Hypotension             | transient orthostatic hypotension, No Rx    | symptoms correctable with oral fluids Rx | requires IV fluids; no |
|                         |                                              |                                     | hospitalization      |
| Pericarditis            | minimal effusion                           | mild/moderate asymptomatic effusion, no Rx | symptomatic effusion; |
|                         |                                              |                                      | pain; EKG changes    |
| Hemorrhage, Blood Loss  | microscopic/occult                          | mild, no transfusion               | gross blood loss;    |
|                         |                                              |                                      | 1-2 units transfused  |
|                         |                                              |                                      | massive blood loss;  |
|                         |                                              |                                      | > 3 units transfused  |

---

Section VIII: Appendices  
Monitoring and Reporting Adverse Events  
February 6, 2003
# Appendix: WHO Toxicity Grading Scale for Determining the Severity of Adverse Events

## Respiratory

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Description</th>
<th>Severity</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>Transient or no Rx</td>
<td>Treatment associated cough</td>
<td>Uncontrolled</td>
</tr>
<tr>
<td>Bronchospasm, Acute</td>
<td>Transient or no Rx; FEV1 &lt; 80% - 70% or peak flow</td>
<td>Requires Rx normalized with bronchodilator; FEV1 25% - 50% or peak flow</td>
<td>Cyanosis; FEV1 &lt; 25% or peak flow or intubated</td>
</tr>
</tbody>
</table>

## Gastrointestinal

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Description</th>
<th>Severity</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomatitis</td>
<td>Mild discomfort, no limits on activity</td>
<td>Some limits on eating/drinking</td>
<td>Eating/talking very limited</td>
</tr>
<tr>
<td>Nausea</td>
<td>Mild discomfort, maintains reasonable intake</td>
<td>Moderate discomfort; intake decreased significantly; some activity limited</td>
<td>Severe discomfort; no significant intake; activities limited</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Transient or moderate emesis</td>
<td>Occasional/moderate vomiting</td>
<td>Orthostatic hypotension or IV fluids required</td>
</tr>
<tr>
<td>Constipation</td>
<td>Mild</td>
<td>Severe</td>
<td>Hypotensive shock or hospitalization required for IV fluid therapy</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Transient or 3-4 loose stools/day</td>
<td>5-7 loose stools/day</td>
<td>Orthostatic hypotension or &gt; 7 loose stools/day or required IV fluids</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypotensive shock or hospitalization for IV fluid therapy required</td>
</tr>
</tbody>
</table>

## Neuro & Neuromuscular

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Description</th>
<th>Severity</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuro-Cerebellar</td>
<td>Slight incoordination, dysdiadochokinesia</td>
<td>Intention tremor, dysmetria, slurred speech, nystagmus</td>
<td>Locomotor ataxia</td>
</tr>
<tr>
<td>Mood</td>
<td>Mild anxiety or depression</td>
<td>Severe anxiety or depression or mania; needs assistance</td>
<td>Acute psychosis; incapacitated, requires hospitalization</td>
</tr>
<tr>
<td>Neuro Control (ADL = activities of daily living)</td>
<td>Mild difficulty concentrating; no Rx; mild confusion/agitation; ADL unaffected</td>
<td>Moderate confusion/agitation some limitation of ADL; minimal Rx</td>
<td>Severe confusion/agitation needs assistance for ADL; therapy required</td>
</tr>
<tr>
<td>Muscle Strength</td>
<td>Subjective weakness no objective symptoms/signs</td>
<td>Mild objective signs/symptoms no decrease in function</td>
<td>Objective weakness function limited</td>
</tr>
</tbody>
</table>
### WHO TOXICITY GRADING SCALE FOR DETERMINING THE SEVERITY OF ADVERSE EVENTS

<table>
<thead>
<tr>
<th>OTHER PARAMETERS</th>
<th>Others</th>
<th>Fever: oral, &gt; 12 hours</th>
<th>Headache</th>
<th>Fatigue</th>
<th>Allergic Reaction</th>
<th>Local Reaction</th>
<th>Macrocutanous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>37.7 - 38.5 °C or 100.0 - 101.5 °F</td>
<td>mild, no Rx therapy</td>
<td>no decrease in ADL</td>
<td>pruritus without rash</td>
<td>tenderness or erythema</td>
<td>erythema; pruritus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>38.6 - 39.5 °C or 101.6 - 102.9 °F</td>
<td>transient, moderate; Rx required</td>
<td>normal activity decreased 25-50%</td>
<td>localized urticaria</td>
<td>induration &lt; 10 cm or phlebitis or inflammation</td>
<td>diffus, maculo papular rash, dry desquamation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>39.6 - 40.5 °C or 103 - 105 °F</td>
<td>severe; responds to initial narcotic therapy</td>
<td>normal activity decreased &gt; 50%, can’t work</td>
<td>generalized urticaria; angioedema</td>
<td>induration &gt; 10 cm or ulceration</td>
<td>vesiculation, moist desquamation, or ulceration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; 40 °C or &gt; 105 °F</td>
<td>intractable; required repeated narcotic therapy</td>
<td>unable to care for self</td>
<td>anaphylaxis</td>
<td>necrosis</td>
<td>exfoliative dermatitis, mucous membrane involvement or erythema, multiforme or suspected Stevens-Johnson or necrosis requiring surgery</td>
</tr>
</tbody>
</table>

ANNEX H. MEDICATION ERROR REPORTING AND PREVENTION SCALE

NCC MERP Index for Categorizing Medication Errors

Category A: Events that have the capacity to cause harm

Category B: An error occurred that the error did not reach the patient (ie, “error of omission” does not reach the patient)

Category C: An error occurred that reached the patient but did not cause patient harm

Category D: An error occurred that reached the patient and required monitoring to ensure that it did not result in a serious adverse event to the patient

Category E: An error occurred that reached the patient and required monitoring to ensure that it did not result in a serious adverse event to the patient and/or required intervention to reduce harm

Category F: An error occurred that reached the patient and required monitoring to ensure that it did not result in a serious adverse event to the patient and/or required intervention to reduce harm

Category G: An error occurred that reached the patient and required monitoring to ensure that it did not result in a serious adverse event to the patient and/or required intervention to reduce harm and/or resulted in a serious adverse event to the patient

Category H: An error occurred that may have contributed to or resulted in the patient's death

NCC MERP Index for Categorizing Medication Errors Algorithm

© 2002 National Coordinating Council for Medication Error Reporting and Prevention


National Coordinating Council for Medication Error Reporting and Prevention Definitions

Harm
Impairment of the physical, emotional, or psychological function or structure of the body and/or pain resulting therefrom.

Monitoring
To observe or record relevant physiological or psychological signs.

Intervention
May include change in therapy or active medical/surgical treatment.

Intervention Necessary to Sustain Life
Includes cardiovascular and respiratory support (e.g., CPR, defibrillation, incubation, etc.)

Error, Harm
Error, Harm
Error, Death

No Error

43
ANNEX I. PATIENT ALERT CARD (ENGLISH)

Patient name: .................................................................

Date of birth: ........................................... Gender: M ☐  F
Height: .........................................................
ID/passport number: ...........................................

Place of issue of the alert card: PV subcommittee of Hospital...........................................

Date when the card was issued: ....../....../......

Responsible medicine: ..........................................

Types of intolerance:
..................................................................................................................................................
..................................................................................................................................................

Please hold always this card with you to be presented to any health care provider in any consultation session.

Itwaie iteka iyi karita kandi wibuke kuyerekana muganga mu gihecyose ugiye kwivuza.

Signature and stamp of PV subcommittee
ANNEX J. PATIENT ALERT CARD (KINYARWANDA)

amazina y’umurwayi………………………………………………………………………………

Igihe yavukiye cyangwa imyaka: ……………………………
Igitsina : Gabo □ Gore □
Uburebure: ……………………………………………
Nimero y’indangamuntu/pasiporo: ………………………

Aho iyo karita yandikiwe: Ibitaro bya……………………………………

Itariki iyo karita yandikiweho: ....../……/……

Ubwoko b’ingaruka mbi yatewe n’umuti: ……………………………………………
……………………………………………………………………………………………………

Izina/ubwoko ry’umuti wateye icyo kibazo:…………………………………………………………

*Itwaze iteka iyi karita kandi wibuke kuyereka muganga mu gihecyose ugiye kwivuza.*
*Kasha y’ibitaro handikiwe ino karita*
ANNEX K. GLOSSARY OF MEDICINE SAFETY TERMS

http://psnet.ahrq.gov/glossary.aspx

Adverse medicine reaction (AMR)/adverse drug reaction (ADR)
A response to a medicine which is noxious and unintended, and which occurs at a dose normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.

The term adverse drug reaction should be considered for harmful or seriously unpleasant effects occurring at doses intended for therapeutic, prophylactic or diagnostic effect and which calls for reduction of dose or withdrawal of the drug and/or forecast hazard from future administration.

Adverse event /adverse experience
Any untoward medical occurrence that may present during treatment with a pharmaceutical products but which does not necessarily have a causal relationship with the treatment.

Medication error
A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.


Medicine/Drug
A pharmaceutical product, used in or on human body for the prevention (prophylaxis, mitigation diagnosis) or treatment of disease, or for the modification of physiological function.

Medicine safety surveillance
The processes involved in the collection, collation, analysis, and dissemination of data and other activities carried out in relations to safeguarding the safety and effectiveness of pharmaceuticals and related products

Medicine safety system
All organisations, institutions, and resources that contribute to efforts, whether in personal health care, public health services or through intersectorial initiatives, whose primary purpose is to protect the public from harm related to the use of medicines.

Periodic safety update report
A periodic safety update report is an update of the worldwide safety experience of a product obtained at defined times post registration.
Pharmacovigilance
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems. Recently, its concerns have been widened to include herbals, traditional and complementary medicines, blood products, biologicals, medical devices and vaccines.

Serious adverse event
Serious adverse event is any untoward occurrence that
1. Is life-threatening or fatal
2. Causes or prolongs hospital admission
3. Causes persistent incapacity or disability
4. Concerns misuse or dependence
5. Causes congenital anomaly/birth defect

Signal
A signal refers to “reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.” Usually more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information.

Side effect
Any unintended effect of a pharmaceutical products occurring at doses normally used in patients, which is related to the pharmacological proprieties of the medicine

Spontaneous reporting
A system whereby case reports of adverse drug events are voluntarily submitted by health professionals and pharmaceutical manufacturers to the national regulatory authority/pharmacovigilance centre

Toxicity
Toxicity implies cell damage from a direct action of the drug, often at a high dose, e.g., liver damage from paracetamol overdose.

Unexpected adverse reaction
An adverse reaction, the nature or severity of which is not consistent with domestic labeling or market authorization, or expected from the characteristics of the drug.

Aims of pharmacovigilance
The specific aims of pharmacovigilance are to—
- Improve patient care and safety in relation to the use of medicines and all medical and paramedical interventions
- Improve public health and safety in relation to the use of medicines
- Detect problems suspected to be caused by medicines and communicate the findings in a timely manner
- Contribute to the assessment of benefit, harm, effectiveness and risk of medicines, leading to the prevention of harm and maximization of benefits;
• Encourage safe, rational and more effective (including cost-effective) use of medicines;
• Promote understanding, education and clinical training in pharmacovigilance and its effective communication to the public.
Annex 13 : Definition and classification of ADRs

WHO defines adverse reaction as a response to a medicine which is noxious and unintended, and which occurs at doses normally used in patients. In this prescription, it is of importance that it concerns the response of a patient in which individual factors may play an important role, and that the phenomenon is noxious.

A classification of ADRs reveals how they are related and draws attention to the common factors involved in the cause of reactions within the same group, thus enabling similar steps to be taken to treat or prevent them. Adverse drug reactions are categorized as Type A, Type B, or Type C in this method of classification.

**Type A (augmented) adverse drug reactions**
- These reactions are the result of an exaggerated, but otherwise normal pharmacological action of a drug given in the usual therapeutic doses.
- Type A reactions are largely predictable on the basis of a drug’s known pharmacology.
- They are usually dose-dependant and although their incidence and morbidity in the community is often high, their mortality is generally low.

**Type B (bizarre) adverse drug reactions**
- These reactions are totally aberrant effects that are not expected from the known pharmacological actions of a drug when given in the usual therapeutic doses to a patient whose body handles the drug in a normal way.
- They are usually unpredictable and are not observed during conventional pharmacological and toxicological screening programs.
- Although their incidence and morbidity are low, their mortality may be high.

**Type C adverse drug reactions**
- These reactions refer to situations where the use of a drug, often for unknown reasons, increases the frequency of a “spontaneous” disease.
- They may be both serious and common and may have pronounced effects on public health.
- They may also be coincidental and often concern long-term effects. There is often no suggestive time relationship and the connection may be very difficult to prove.